Ascentage Pharma Group International - ADR

Ascentage Pharma Group International is an American Depository Receipt (ADR) representing shares in a China-based biopharmaceutical company. This financial instrument provides U.S. investors with a means to invest in Ascentage Pharma while addressing differences in currency, tax treatment, and regulations. The company focuses on the discovery and development of innovative therapies for cancers, hepatitis B, and age-related diseases. Ascentage Pharma leverages its expertise in apoptosis, a key biological mechanism in cancer treatment, to create targeted therapies addressing significant unmet medical needs. The ADR facilitates Ascentage’s entry into broader capital markets by increasing liquidity and attracting a diverse group of investors. Consequently, it plays a crucial role in integrating the growth of Chinese biotech innovation with international investment opportunities, contributing to the global advancement in pharmaceutical research.